In recent years, numerous real-life studies, mainly focusing on anti-IL5 and anti-IL5r pharmacotherapeutic strategies, have also been conducted with the aim of identifying categories of patients with severe asthma who could be considered super responders, and what the clinical, functional and biological characteristics of these patients were [8,9,10,11,12]. The gene discussed is IL5; the disease is asthma.